DCM
VYGR icon

DAFNA Capital Management’s Voyager Therapeutics VYGR Stock Holding History

DAFNA Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-157,000
Closed -$2.61M – 80
2017
Q4 		$2.61M Buy
157,000
+39,741
+34% +$681K 1.4% 26
2017
Q3 		$2.41M Sell
117,259
-87,549
-43% -$988K 1.5% 22
2017
Q2 		$1.83M Buy
204,808
+133,488
+187% +$1.34M 1.31% 28
2017
Q1 		$944K Buy
+71,320
New +$865K 0.8% 37

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

DAFNA Capital Management's VYGR Position: Q1 2018 in Review

DAFNA Capital Management sold out of Voyager Therapeutics (VYGR) in Q1 2018, closing a stake of 157,000 shares — an estimated $2.61M sold.

DAFNA Capital Management first reported a position in VYGR in Q1 2017 and held it in 4 quarters. The position peaked at $2.61M in Q4 2017. 108 funds tracked by Wall St. Rank hold VYGR as of Q1 2018.

  • DAFNA Capital Management reported no remaining Voyager Therapeutics position as of Q1 2018 after selling out during the quarter.
  • DAFNA Capital Management sold 157,000 Voyager Therapeutics shares in Q1 2018, an estimated $2.61M.
  • DAFNA Capital Management first reported a position in Voyager Therapeutics in Q1 2017 and held it in 4 quarters.
  • DAFNA Capital Management's Voyager Therapeutics position peaked at $2.61M in Q4 2017.
  • 108 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2018.

Based on DAFNA Capital Management's 13F filing for Q1 2018, filed 15 May 2018.